Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cyclo Therapeutics (CYTH)
NASDAQ:CYTH
RESEARCH TOOLSreports
Holding CYTH?
Track your performance easily
CYTH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.59 - $2.12
Previous Close$0.7
Volume10.83K
Average Volume (3M)41.08K
Market Cap
$19.59M
Enterprise Value$31.39M
Total Cash (Recent Filing)$928.01K
Total Debt (Recent Filing)$12.21M
Price to Earnings (P/E)―
Beta1.83
Next Earnings
Mar 17, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.90
Shares Outstanding28,768,055
10 Day Avg. Volume23,370
30 Day Avg. Volume41,078
Standard Deviation0.22
R-Squared0.00711
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)-1.51
Price to Sales (P/S)22.50
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue36.05
Enterprise Value/Gross Profit31.64
Enterprise Value/Ebitda-1.30
Forecast
1Y Price Target
$0.95Price Target Upside35.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Cyclo Therapeutics News
PremiumCompany Announcements
Cyclo Therapeutics’ Merger and Financial Arrangements with Rafael Holdings
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentThe completion of enrollment in the largest controlled pivotal study for NPC1 ever conducted is a major milestone, with top-line data expected from the 48-week interim analysis in the first quarter of 2025.
Institutional SupportCyclo Therapeutics has institutional support from Rafael Holdings, which could continue to support the company as it aims to reach interim data for Trappsol Cyclo expected in the first quarter of 2025.
Patent And Intellectual PropertyThe company received notice from the European Patent Office of a decision to grant a European patent application.
Bears Say
EarningsThe company's earnings per share (EPS) was $(0.21), falling short of both the analyst's and consensus estimate of $(0.17), highlighting a disappointing earnings performance.
Financial PerformanceThe company reported operating expenses of $5.8 million, which exceeded the analyst's estimate of $5.1 million, indicating higher-than-expected costs.
Stock ValuationThe merger's offer price represents a 25% discount to CYTH’s closing price on August 21, suggesting a lower valuation for CYTH shares.
---
Ownership Overview
8.54% Insiders
2.13% Mutual Funds
4.64% Other Institutional Investors
82.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
CYTH FAQ
What was Cyclo Therapeutics’s price range in the past 12 months?
Cyclo Therapeutics lowest stock price was $0.59 and its highest was $2.12 in the past 12 months.
What is Cyclo Therapeutics’s market cap?
Currently, no data Available
When is Cyclo Therapeutics’s upcoming earnings report date?
Cyclo Therapeutics’s upcoming earnings report date is Mar 17, 2025 which is in 115 days.
How were Cyclo Therapeutics’s earnings last quarter?
Cyclo Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.307 earnings per share for the quarter, missing the consensus estimate of -$0.157 by -$0.15.
Is Cyclo Therapeutics overvalued?
According to Wall Street analysts Cyclo Therapeutics’s price is currently Undervalued.
Does Cyclo Therapeutics pay dividends?
Cyclo Therapeutics does not currently pay dividends.
What is Cyclo Therapeutics’s EPS estimate?
Cyclo Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cyclo Therapeutics have?
Cyclo Therapeutics has 28,768,055 shares outstanding.
What happened to Cyclo Therapeutics’s price movement after its last earnings report?
Cyclo Therapeutics reported an EPS of -$0.307 in its last earnings report, missing expectations of -$0.157. Following the earnings report the stock price went up 4.225%.
Which hedge fund is a major shareholder of Cyclo Therapeutics?
Currently, no hedge funds are holding shares in CYTH
---
Cyclo Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$0.95 (35.91% Upside)
$0.95 (35.91% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.62%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.13%
Trailing 12-Months
Company Description
Cyclo Therapeutics
Cyclo Therapeutics, Inc. engages in the development of cyclodextrin-based biopharmaceuticals for the treatment of disease. Its product candidates include Trappsol Cyclo, which treats Neimann-Pick Type C disease. The firm focuses on the development and commercialization of innovative cyclodextrin-based products for the treatment of people with serious and life threatening rare diseases and medical conditions. The company was founded by Charles E. Rick Strattan on August 9, 1990 and is headquartered in Gainesville, FL.
---
CYTH Stock 12 Month Forecast
Average Price Target
$0.95
▲(35.91% Upside)
Technical Analysis
Best Analysts Covering CYTH
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-29.05%
assigned a buy rating 3 months ago
Copying Lucas Ward's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -29.05% per trade.
---